Hematopoietic stem cells (HSCs) are an important target cell population for gene therapy since they can reconstitute the entire hematopoietic system. HSC-enriched cell populations can be recognized based on cell surface marker expression, such as CD34, which is broadly expressed on immature and partially differentiated cells. In mice, co-expression of CD34 and CD105 was previously shown to be relatively more specific for the most immature, long-term repopulating HSCs. Here, we evaluated whether CD105, which is expressed on 30%–80% of CD34+ cells, is a marker also for human long-term repopulating HSCs. Therefore, we tracked the mature progeny of CD34+ cells transduced with the CD105-targeted lentiviral vector CD105-LV in xenotolerant mice. Transduction was blocked with soluble CD105 protein confirming specificity. Importantly, CD105-LV transduced human CD34+ cells engrafted in NOD-scid IL2Rγ−/− mice with up to 20% reporter gene-positive cells detected long term in all human hematopoietic lineages in bone marrow (BM), spleen, and blood. In addition, competitive repopulation experiments in mice showed a superior engraftment of CD105-LV transduced CD34+ cells in BM and spleen compared with cells transduced with a conventional nontargeted lentiviral vector. Thus, human CD34+/CD105+ cells are enriched for early HSCs with high repopulating capacity. Targeting this cell population with CD105-LV offers a novel gene transfer strategy to reach high engraftment rates of transduced cells and highlights the applicability of receptor-targeted vectors to trace cell subsets offering an alternative to prospective isolation by surface markers.
Get full access to this article
View all access options for this article.
References
1.
AiutiA and RoncaroloMG. (2009). Ten years of gene therapy for primary immune deficiencies. Hematology Am Soc Hematol Educ Program. 682–689. DOI: 10.1182/asheducation-2009.1.682.
2.
NaldiniL. (2011). Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet, 12:301–315.
3.
KaufmannKB, BüningH, GalyA, SchambachA and GrezM. (2013). Gene therapy on the move. EMBO Mol Med, 5:1642–1661.
4.
GrezM, ReichenbachJ, SchwäbleJ, SegerR, DinauerMC and ThrasherAJ. (2011). Gene therapy of chronic granulomatous disease: the engraftment dilemma. Mol Ther, 19:28–35.
5.
GuenecheaG, GanOI, DorrellC and DickJE. (2001). Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol, 2:75–82.
6.
McKenzieJL, GanOI, DoedensM, WangJC and DickJE. (2006). Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol, 7:1225–1233.
7.
FinkelshteinD, WermanA, NovickD, BarakS and RubinsteinM. (2013). LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A, 110:7306–7311.
8.
AmiracheF, LévyC, CostaC, MangeotP, TorbettBE, WangCX, NègreD, CossetF and VerhoeyenE. (2014). Mystery solved: VSV-G-LVs do not allow efficient gene transfer into unstimulated T cells, B cells, and HSCs because they lack the LDL receptor. Blood, 123:1422–1424.
9.
FunkeS, MaisnerA, MühlebachMD, KoehlU, GrezM, CattaneoR, CichutekK and BuchholzCJ. (2008). Targeted cell entry of lentiviral vectors. Mol Ther, 16:1427–1436.
10.
KneisslS, ZhouQ, SchwenkertM, CossetF, VerhoeyenE and BuchholzCJ. (2013). CD19 and CD20 targeted vectors induce minimal activation of resting B lymphocytes. PLoS One, 8:e79047
11.
ZhouQ, SchneiderIC, EdesI, HoneggerA, BachP, SchönfeldK, SchambachA, WelsWS, KneisslS, UckertW and BuchholzCJ. (2012). T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing. Blood, 120:4334–4342.
12.
AgeichikA, BuchholzCJ and CollinsMK. (2011). Lentiviral vectors targeted to MHC II are effective in immunization. Hum Gene Ther, 22:1249–1254.
13.
AnlikerB, AbelT, KneisslS, HlavatyJ, CaputiA, BrynzaJ, SchneiderIC, MünchRC, PetznekH, et al. (2010). Specific gene transfer to neurons, endothelial cells and hematopoietic progenitors with lentiviral vectors. Nat Methods, 7:929–935.
14.
AbelT, El FilaliE, WaernJ, SchneiderIC, YuanQ, MünchRC, HickM, WarneckeG, MadrahimovN, et al. (2013). Specific gene delivery to liver sinusoidal and artery endothelial cells. Blood, 122:2030–2038.
15.
MünchRC, MühlebachMD, SchaserT, KneisslS, JostC, PlückthunA, CichutekK and BuchholzCJ. (2011). DARPins: an efficient targeting domain for lentiviral vectors. Mol Ther, 19:686–693.
16.
BuchholzCJ, MühlebachMD and CichutekK. (2009). Lentiviral vectors with measles virus glycoproteins—dream team for gene transfer?. Trends Biotechnol, 27:259–265.
17.
St-JacquesS, CymermanU, PeceN and LetarteM. (1994). Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-beta binding protein of endothelial and stromal cells. Endocrinology, 134:2645–2657.
18.
WarringtonK, HillarbyMC, LiC, LetarteM and KumarS. (2005). Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res, 25:1851–1864.
19.
ChenC, LiM, de GraafD, MontiS, GöttgensB, SanchezM, LanderES, GolubTR, GreenAR and LodishHF. (2002). Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells. Proc Natl Acad Sci U S A, 99:15468–15473.
20.
ChenC, LiL, LiM and LodishHF. (2003). The endoglin(positive) sca-1(positive) rhodamine(low) phenotype defines a near-homogeneous population of long-term repopulating hematopoietic stem cells. Immunity, 19:525–533.
21.
RoquesM, DurandC, GautierR, CantoP, Petit-CocaultL, YvernogeauL, DunonD, SouyriM and JaffredoT. (2012). Endoglin expression level discriminates long-term hematopoietic from short-term clonogenic progenitor cells in the aorta. Haematologica, 97:975–979.
22.
PierelliL, ScambiaG, BonannoG, RutellaS, PuggioniP, BattagliaA, MozzettiS, MaroneM, MenichellaG, et al. (2000). CD34+/CD105+ cells are enriched in primitive circulating progenitors residing in the G0 phase of the cell cycle and contain all bone marrow and cord blood CD34+/CD38low/- precursors. Br J Haematol, 108:610–620.
23.
PierelliL, BonannoG, RutellaS, MaroneM, ScambiaG and LeoneG. (2001). CD105 (endoglin) expression on hematopoietic stem/progenitor cells. Leuk Lymphoma, 42:1195–1206.
ZuffereyR, NagyD, MandelRJ, NaldiniL and TronoD. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol, 15:871–875.
26.
DemaisonC, ParsleyK, BrounsG, ScherrM, BattmerK, KinnonC, GrezM and ThrasherAJ. (2002). High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther, 13:803–813.
27.
BrehmMA, ShultzLD, LubanJ and GreinerDL. (2013). Overcoming current limitations in humanized mouse research. J Infect Dis 208, (Suppl 2)::S125–S130.
28.
NassiriF, CusimanoMD, ScheithauerBW, RotondoF, FazioA, YousefGM, SyroLV, KovacsK and LloydRV. (2011). Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy. Anticancer Res, 31:2283–2290.
29.
HatzfeldJ, LiML, BrownEL, SookdeoH, LevesqueJP, O'TooleT, GurneyC, ClarkSC and HatzfeldA. (1991). Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor beta 1 or Rb oligonucleotides. J Exp Med, 174:925–929.
30.
AiutiA, BiascoL, ScaramuzzaS, FerruaF, CicaleseMP, BaricordiC, DionisioF, CalabriaA, GiannelliS, et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341:123–151.
CartierN, Hacein-Bey-AbinaS, BartholomaeCC, VeresG, SchmidtM, KutscheraI, VidaudM, AbelU, Dal-CortivoL, et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science, 326:818–823.
33.
GéronimiF, RichardE, Redonnet-VernhetI, Lamrissi-GarciaI, LalanneM, GedC, Moreau-GaudryF and de VerneuilH. (2003). Highly efficient lentiviral gene transfer in CD34+ and CD34+/38-/lin- cells from mobilized peripheral blood after cytokine prestimulation. Stem Cells, 21:472–480.
34.
AillesL, SchmidtM, Santoni de SioFR, GlimmH, CavalieriS, BrunoS, PiacibelloW, von KalleC and NaldiniL. (2002). Molecular evidence of lentiviral vector-mediated gene transfer into human self-renewing, multi-potent, long-term NOD/SCID repopulating hematopoietic cells. Mol Ther, 6:615–626.
35.
AmsellemS, RavetE, FichelsonS, PflumioF and Dubart-KupperschmittA. (2002). Maximal lentivirus-mediated gene transfer and sustained transgene expression in human hematopoietic primitive cells and their progeny. Mol Ther, 6:673–677.
36.
KnightS, CollinsM and TakeuchiY. (2013). Insertional mutagenesis by retroviral vectors: current concepts and methods of analysis. Curr Gene Ther, 13:211–227.
37.
GlimmH, OhIH and EavesCJ. (2000). Human hematopoietic stem cells stimulated to proliferate in vitro lose engraftment potential during their S/G(2)/M transit and do not reenter G(0). Blood, 96:4185–4193.
38.
KittlerEL, PetersSO, CrittendenRB, DebatisME, RamshawHS, StewartFM and QuesenberryPJ. (1997). Cytokine-facilitated transduction leads to low-level engraftment in nonablated hosts. Blood, 90:865–872.
39.
HanawaH, KellyPF, NathwaniAC, PersonsDA, VandergriffJA, HargroveP, VaninEF and NienhuisAW. (2002). Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther, 5:242–251.
40.
BellAJ, FegenD, WardM and BankA. (2010). RD114 envelope proteins provide an effective and versatile approach to pseudotype lentiviral vectors. Exp Biol Med, 235:1269–1276.
41.
VerhoeyenE, WiznerowiczM, OlivierD, IzacB, TronoD, Dubart-KupperschmittA and CossetF. (2005). Novel lentiviral vectors displaying “early-acting cytokines”. selectively promote survival and transduction of NOD/SCID repopulating human hematopoietic stem cells. Blood, 106:3386–3395.
42.
FrechaC, CostaC, NègreD, AmiracheF, TronoD, RioP, BuerenJ, CossetF and VerhoeyenE. (2012). A novel lentiviral vector targets gene transfer into human hematopoietic stem cells in marrow from patients with bone marrow failure syndrome and in vivo in humanized mice. Blood, 119:1139–1150.
43.
Girard-GagnepainA, AmiracheF, CostaC, LévyC, FrechaC, FusilF, NègreD, LavilletteD, CossetF and VerhoeyenE. (2014). Baboon envelope pseudotyped lentiviral vectors outperform VSV-G pseudotyped lentiviral vectors for gene transfer into cytokine-stimulated and resting hematopoietic stem cells. Blood, 124:1221–1231.
44.
BrendelC, GoebelB, AbrißD, BrugmanM, KneisslS, SchwäbleJ, KaufmannKB, Müller-KullerU, KunkelH, et al. (2015). CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells. Mol Ther, 23:63–70.
45.
LinC, XinZ, DaiJ and LueTF. (2013). Commonly used mesenchymal stem cell markers and tracking labels: limitations and challenges. Histol Histopathol, 28:1109–1116.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
